These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27404789)

  • 1. Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing.
    Ng HI; Fernando GJ; Depelsenaire AC; Kendall MA
    Sci Rep; 2016 Jul; 6():29368. PubMed ID: 27404789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses.
    Fernando GJ; Chen X; Primiero CA; Yukiko SR; Fairmaid EJ; Corbett HJ; Frazer IH; Brown LE; Kendall MA
    J Control Release; 2012 Apr; 159(2):215-21. PubMed ID: 22306334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.
    Fernández-Tejada A; Chea EK; George C; Gardner JR; Livingston PO; Ragupathi G; Tan DS; Gin DY
    Bioorg Med Chem; 2014 Nov; 22(21):5917-23. PubMed ID: 25284254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
    Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
    J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Immunogenicity and Protective Efficacy of a
    Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
    mSphere; 2019 May; 4(3):. PubMed ID: 31043512
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
    Lacaille-Dubois MA
    Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    J Med Chem; 2019 Feb; 62(3):1669-1676. PubMed ID: 30656932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity.
    Boyaka PN; Marinaro M; Jackson RJ; van Ginkel FW; Cormet-Boyaka E; Kirk KL; Kensil CR; McGhee JR
    J Immunol; 2001 Feb; 166(4):2283-90. PubMed ID: 11160283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.
    Sasaki S; Sumino K; Hamajima K; Fukushima J; Ishii N; Kawamoto S; Mohri H; Kensil CR; Okuda K
    J Virol; 1998 Jun; 72(6):4931-9. PubMed ID: 9573261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predominant Quillaja Saponaria fraction, QS-18, is safe and effective when formulated in a liposomal murine cancer peptide vaccine.
    Zhou S; Song Y; Nilam A; Luo Y; Huang WC; Long MD; Lovell JF
    J Control Release; 2024 May; 369():687-695. PubMed ID: 38575073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
    J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
    Bhatnagar N; Kim KH; Subbiah J; Park BR; Ko EJ; Seong BL; Kang SM
    Antiviral Res; 2022 Jan; 197():105229. PubMed ID: 34933043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants.
    He L; Sun B; Guo Y; Yan K; Liu D; Zang Y; Jiang C; Zhang Y; Kong W
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108216. PubMed ID: 34634689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
    Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C
    J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles.
    Jiang B; Estes MK; Barone C; Barniak V; O'Neal CM; Ottaiano A; Madore HP; Conner ME
    Vaccine; 1999 Feb; 17(7-8):1005-13. PubMed ID: 10067709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
    Moore A; McCarthy L; Mills KH
    Vaccine; 1999 Jun; 17(20-21):2517-27. PubMed ID: 10418898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.